Article
ARID1A suppresses R-loop-mediated STING-type I interferon pathway activation of anti-tumor immunity.
Cell - 20 Jun 2024
Maxwell Matthew B, Hom-Tedla Marianne S, Yi Jawoon, Li Shitian, Rivera Samuel A, Yu Jingting, Burns Mannix J, McRae Helen M, Stevenson Braden T, Coakley Katherine E, Ho Josephine, Gastelum Kameneff Bojorquez, Bell Joshua C, Jones Alexander C, Eskander Ramez N, Dykhuizen Emily C, Shadel Gerald S, Kaech Susan M, Hargreaves Diana C
Abstract excerpt
Clinical trials have identified ARID1A mutations as enriched among patients who respond favorably to immune checkpoint blockade (ICB) in several solid tumor types independent of microsatellite instability. We show that ARID1A loss in murine models is sufficient to induce anti-tumor immune phenotypes observed in ARID1A mutant human cancers, including increased CD8+ T cell infiltration and cytolytic activity....
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.